Your browser doesn't support javascript.
Objectively characterizing Huntington's disease using a novel upper limb dexterity test.
Woodgate, Samuel; Morgan-Jones, Philippa; Clinch, Susanne; Drew, Cheney; Playle, Rebecca; Bennasar, Mohamed; Hicks, Yulia; Holt, Catherine; Bachoud-Lévi, Anne-Catherine; Massart, Renaud; Craufurd, David; Kirby, Nigel; Hamana, Katy; Schubert, Robin; Reilmann, Ralf; Rosser, Anne; Busse, Monica.
  • Woodgate S; Cardiff School of Engineering, Cardiff University, Cardiff, United Kingdom.
  • Morgan-Jones P; NMRI, School of Medicine, Cardiff University, Cardiff, United Kingdom.
  • Clinch S; Cardiff School of Engineering, Cardiff University, Cardiff, United Kingdom.
  • Drew C; Centre for Trials Research, Cardiff University, 4th Floor, Neuadd Meirionnydd, Heath Park, Cardiff, CF14 4YS, United Kingdom.
  • Playle R; Brain Repair Group, School of Biosciences, Cardiff University, Cardiff, United Kingdom.
  • Bennasar M; Centre for Trials Research, Cardiff University, 4th Floor, Neuadd Meirionnydd, Heath Park, Cardiff, CF14 4YS, United Kingdom.
  • Hicks Y; Centre for Trials Research, Cardiff University, 4th Floor, Neuadd Meirionnydd, Heath Park, Cardiff, CF14 4YS, United Kingdom.
  • Holt C; School of Computing and Communications, The Open University, Milton Keynes, United Kingdom.
  • Bachoud-Lévi AC; Cardiff School of Engineering, Cardiff University, Cardiff, United Kingdom.
  • Massart R; Cardiff School of Engineering, Cardiff University, Cardiff, United Kingdom.
  • Craufurd D; Assistance Publique -Hopitaux de Paris, National Centre of Reference for Huntington's Disease, Neurology Department Henri Mondor Hospital, Creteil, France.
  • Kirby N; INSERM U955 01, Institut Mondor de Recherche Biomédicale, UPEC, Créteil-Ecole Normale Supérieure, PSL, Paris, France.
  • Hamana K; Assistance Publique -Hopitaux de Paris, National Centre of Reference for Huntington's Disease, Neurology Department Henri Mondor Hospital, Creteil, France.
  • Schubert R; INSERM U955 01, Institut Mondor de Recherche Biomédicale, UPEC, Créteil-Ecole Normale Supérieure, PSL, Paris, France.
  • Reilmann R; Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
  • Rosser A; Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.
  • Busse M; Centre for Trials Research, Cardiff University, 4th Floor, Neuadd Meirionnydd, Heath Park, Cardiff, CF14 4YS, United Kingdom.
J Neurol ; 268(7): 2550-2559, 2021 Jul.
Article in English | MEDLINE | ID: covidwho-1336077
ABSTRACT

BACKGROUND:

The Clinch Token Transfer Test (C3t) is a bi-manual coin transfer task that incorporates cognitive tasks to add complexity. This study explored the concurrent and convergent validity of the C3t as a simple, objective assessment of impairment that is reflective of disease severity in Huntington's, that is not reliant on clinical expertise for administration.

METHODS:

One-hundred-and-five participants presenting with pre-manifest (n = 16) or manifest (TFC-Stage-1 n = 39; TFC-Stage-2 n = 43; TFC-Stage-3 n = 7) Huntington's disease completed the Unified Huntington's Disease Rating Scale and the C3t at baseline. Of these, thirty-three were followed up after 12 months. Regression was used to estimate baseline individual and composite clinical scores (including cognitive, motor, and functional ability) using baseline C3t scores. Correlations between C3t and clinical scores were assessed using Spearman's R and visually inspected in relation to disease severity using scatterplots. Effect size over 12 months provided an indication of longitudinal behaviour of the C3t in relation to clinical measures.

RESULTS:

Baseline C3t scores predicted baseline clinical scores to within 9-13% accuracy, being associated with individual and composite clinical scores. Changes in C3t scores over 12 months were small ([Formula see text] ≤ 0.15) and mirrored the change in clinical scores.

CONCLUSION:

The C3t demonstrates promise as a simple, easy to administer, objective outcome measure capable of predicting impairment that is reflective of Huntington's disease severity and offers a viable solution to support remote clinical monitoring. It may also offer utility as a screening tool for recruitment to clinical trials given preliminary indications of association with the prognostic index normed for Huntington's disease.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Huntington Disease Type of study: Diagnostic study / Prognostic study Topics: Long Covid / Variants Limits: Humans Language: English Journal: J Neurol Year: 2021 Document Type: Article Affiliation country: S00415-020-10375-8

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Huntington Disease Type of study: Diagnostic study / Prognostic study Topics: Long Covid / Variants Limits: Humans Language: English Journal: J Neurol Year: 2021 Document Type: Article Affiliation country: S00415-020-10375-8